Upbeat on life sciences
Aisling Capital’s Dennis Purcell believes a change in the dynamics of the pharmaceutical industry spells good fortune for life sciences investors. By Ken MacFadyen.
30 December 2012•2 mins read
Aisling Capital’s Dennis Purcell believes a change in the dynamics of the pharmaceutical industry spells good fortune for life sciences investors. By Ken MacFadyen.
Side Letter: Blended buyouts
3 November 2026 · 3 mins read
Blackstone’s Gray: Some AI investments 'will go awry'
3 November 2026 · 3 mins read
New Mountain’s Klinsky: Single-asset CVs ‘in the first inning’ of PE adoption
3 November 2026 · 4 mins read
Side Letter: Lazard CL launches
2 November 2026 · 3 mins read
Deep Dive: Why Asia-Pacific private equity is shifting from growth to control
2 November 2026 · 10 mins read
TPG targets Q4 close for latest flagship and healthcare fund
29 October 2026 · 2 mins read
Blue Owl's latest GP stakes fund close may slip to Q1 2027
29 October 2026 · 3 mins read
